Your Health, We Care
Fidaxomicin is indicated in adult and pediatric patients aged 6 months and older for the treatment of C. difficile-associated diarrhea (CDAD).
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Fidaxomicin and other antibacterial drugs, Fidaxomicin should be used only to treat infections that are proven or strongly suspected to be caused by C. difficile. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
FDA,2020.05
Fidaxomicin is an innovative drug carefully developed by Optimer, specially designed for the treatment of refractory Clostridium infection, by blocking bacterial RNA polymerase, en···【more】
Article source：Lucius LaosRelease date：2024-08-29Recommended：129
Fidaxomicin is an antibiotic developed by Optimer, which targets the unique mechanism of refractory Clostridium and can effectively inhibit RNA polymerase, ensuring clinically effi···【more】
Article source：Lucius LaosRelease date：2024-08-29Recommended：122
Fidaxomicin is an innovative macrolide antibiotic developed by Optimer, which is designed for the treatment of refractory Clostridium infections with its unique RNA polymerase inhi···【more】
Article source：Lucius LaosRelease date：2024-08-29Recommended：112
Clostridium difficile, a prevalent enteric pathogen, is known to induce profound diarrhea and occasionally necessitate hospitalization. Fidaxomicin, a therapeutic agent, aids in th···【more】
Article source：Lucius LaosRelease date：2024-08-05Recommended：116
Fidaxomicin, a macrolide antibiotic sanctioned by the US FDA in 2011, boasts a distinctive mechanism of action. This medication predominantly hinders the RNA polymerase of bacteria···【more】
Article source：Lucius LaosRelease date：2024-08-05Recommended：129
Fidaxomicin, a potent antibiotic medication, serves as a pivotal remedy for the treatment of diarrheal conditions stemming from a Clostridium difficile infection, showcasing signif···【more】
Article source：Lucius LaosRelease date：2024-08-05Recommended：147
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
